FRANKFURT, Germany May 17 German drugmaker
Bayer won the U.S. Food and Drug Administration's
priority review status for an experimental drug for a difficult
to treat type of blood cancer, bolstering its development
Based on results of a Phase II study, the FDA plans to
review Bayer's copanlisib within six months instead of the usual
10 for use against follicular lymphoma which has returned or
persisted despite at least two prior therapies, the company said
in a statement on Wednesday.
Bayer, which is taking over U.S. seeds group Monsanto
, is trying to follow up in its drug development efforts
on the recent success of blood thinner Xarelto and
anti-blindness treatment Eylea.
"Copanlisib may have a greater success and potential than we
initially anticipated," Bryan Garnier analysts said, adding they
would revise their current peak sales estimate of 600 million
euros ($666 million).
Bayer has said it was targeting peak annual sales of more
than 500 million euros for the compound.
The Phase II trials has previously shown that copanlisib
lead to the cancer receding in close to 60 percent of
($1 = 0.9014 euros)
(Reporting by Ludwig Burger, editing by Louise Heavens)